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Executive Summary 
 The landscape of private genetic testing services is poorly developed in many 
European countries as well as the United States. 
 We have performed a nationwide survey of 18 private genetic testing laboratories 
located in Athens and various other cities in Greece in order to obtain a better 
understanding of the genetic testing services that these centers provide. 
 Our questionnaire included 22 questions on various aspects of genetic testing, such 
as the types of genetic test offered by these private laboratories, their target clientele 
and the marketing channels used to approach them, the cost of the analyses, and 
laboratory accreditation. 
 13 of the 18 private genetic testing laboratories responded to our questionnaire and  
analysis of their responses indicated that although molecular genetic and 
cytogenetic testing tend to predominate, the demand for pharmacogenomic testing is 
steadily growing.  
 In Greece, physicians comprise the main target group for private genetic testing 
laboratories. Generally, they tend to be approached via the Internet, through 
personal contact from sales representatives or at scientific conferences.  
 Although the costs of genetic testing are fairly low in Greece, most genetic 
laboratories either employ or collaborate with a genetic counselor. However, few 
laboratories appear to be properly accredited for the provision of genetic testing 
services.  
 Our study constitutes a critical appraisal of the private genetic testing environment 
in Greece and provides a model for replication in other European countries.   
Abstract 
 In the post-genomic era, we are witnessing rapid progress in the identification of 
the molecular basis of human inherited disorders and the elucidation of genotype-
phenotype relationships. The rate of progress has been driven not only by the 
determination and ongoing decipherment of the human genome sequence but also by the 
advent of new technological developments that have dramatically reduced the costs of 
genetic analysis. As a consequence, a considerable number of genetic testing centers 
have emerged, both in Europe and the United States, which offer a plethora of different 
genetic tests. We have performed a nationwide survey of 18 private genetic testing 
laboratories in Greece to acquire a better understanding of the genetic testing services 
that these centers provide, specifically the types of genetic test offered, the target groups, 
marketing channels, costs of analysis and accreditation. Molecular genetic and 
cytogenetic testing were found to be the predominant types of genetic testing services 
offered although there is an increasing demand for pharmacogenomic testing. The main 
target group for private genetic testing laboratories are physicians who are approached 
via the Internet, through personal contacts from sales representatives, and at scientific 
conferences. Genetic testing costs are fairly low in Greece. Although the majority of 
private genetic laboratories either employ or collaborate with a genetic counselor, few of 
them are accredited for the provision of genetic testing services. This study provides the 
basis for a critical appraisal of the private genetic testing environment in Greece and 
provides a model for replication in other European countries.   
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Introduction 
In recent years, significant advances have been made in our understanding of the genetic 
basis of inherited disorders and the correlations between mutant genotype and clinical 
phenotype, both for monogenic and multifactorial conditions [Chen et al., 2010; Cooper 
et al. 2010]. These advances, in conjunction with the advent of high-throughput genetic 
analysis and deep resequencing, have served to reshape the field of modern medical 
practice [Metzker, 2010] and are reflected in the rapid development of the genetic 
testing industry [Ginsburg and Willard, 2009; Caulfield et al., 2010]. Nowadays, there 
are a wide variety of public entities and private companies that offer a broad range of 
antenatal and postnatal molecular genetic testing services for monogenic and multigene 
disorders, classical and molecular cytogenetics analysis for chromosomal 
rearrangements, pharmacogenomic testing and even predictive genomics for genetic 
disorders. In addition, many laboratories also offer molecular genetic testing services in 
microbiology and virology. At the same time, genetic testing services are becoming 
more affordable so that we can already envisage genome resequencing for as little as 
$1,000 [Davies, 2010].  
However, the rapid expansion of the genetic testing industry has not come without 
problems. In particular, some laboratories still offer genetic analysis services using in-
house (‘home-brew’) kits rather than quality-controlled and certified assays. In addition, 
test results are not invariably interpreted by a qualified professional (e.g., a genetic 
counselor), whereas other laboratories are not yet accredited for the provision of genetic 
testing services [Burnett, 2009]. Moreover, it transpires that, in several cases, genetic 
analysis is routinely conducted without obtaining informed consent from those persons 
requesting the test. This raises serious ethical concerns in relation to the preservation of 
the anonymity of the individuals tested [Gurwitz and Bregman-Eschet, 2009], the fate of 
their genetic material and, most importantly, the safeguarding of test results in order to 
avoid genetic stigmatization [Guttmacher et al., 2010].  
The landscape of private genetic testing services is still poorly developed in many 
parts of Europe and the United States. Hence, a number of different ethical issues often 
arise as a consequence. EuroGenTest (http://www.eurogentest.org) has recently 
attempted to plug this gap by initiating a drive to harmonize genetic testing services in 
Europe. In parallel, OrphaNet (http://www.orpha.net) has attempted to database the 
plethora of genetic testing laboratories in Europe but these efforts have often been 
hampered by the willingness of some laboratories to communicate the requested details 
of their operations. It is therefore clear that, in emerging era of personalized genomics, 
the task of ‘fine mapping’ genetic testing services in Europe is assuming ever greater 
urgency.  
We have initiated nationwide surveys to assess private genetic testing services 
currently available in Greece, not simply from the patients’ and physicians’ point of 
view but also from the test providers’ standpoint. In these surveys, we have aimed to: (a) 
map patients’ and physicians’ needs with respect to the genetic testing industry, (b) 
identify regulatory deficiencies and gaps in the existing legal provision that could be 
rectified by appropriate legislation, and (c) provide a model for the European-wide 
survey of genetic testing laboratories with the ultimate goal of harmonizing genetic 
testing in Europe. Here, we report the results from our initial survey of genetic testing 
providers in Greece.  
 
Methods  
This research study was conducted between March 2010 and December 2010, 
during which 18 private genetic testing laboratories from various cities in Greece (Table 
1), and comprising the bulk of the genetic testing industry in Greece, were invited to 
participate. The names and websites of the participating laboratories will be made 
available upon request.  
The survey addressed issues such as: (a) the collection of qualitative data on the 
types of genetic testing services provided, (b) the laboratories’ clientele, (c) specific 
details of the approach to genetic testing, such as methods of DNA isolation and 
analysis, accreditation, (d) approaches to marketing, and (e) the costs to the consumer of 
the genetic tests being offered. A 21-point questionnaire (Supplementary data online) 
was sent to the laboratories’ scientific and management personnel for self-completion, 
from which quantitative and qualitative data were subsequently generated. 
Pharmacogenomic testing formed an integral part of the questionnaire, since it has 
gradually become an important area of personalized medicine.   
A simple binary approach (No=0, Yes=1) was employed to score the answers 
given. Information provided was then cross-checked from the corresponding websites, 
where available to ensure accuracy and consistency. 
 
Results 
 Thirteen of the 18 private genetic testing laboratories (72.2%) responded to the 
questionnaire. In almost half of all cases, several reminders had to be sent in order to 
elicit a response; this situation may reflect a certain degree of reluctance on the part of 
commercial entities to participate in such surveys (MB Petersen, personal 
communication).  
Our data indicate that most of the surveyed genetic testing laboratories (92.3%) 
are involved in the provision of molecular genetic analysis for inherited disorders, 
followed closely by classical and/or molecular cytogenetic testing (84.6%), and 
molecular genetic testing for microbiology and predictive genomics (76.2%; Fig. 1A). 
By contrast, pharmacogenomic analysis was only offered by 8 of the 13 laboratories that 
completed the survey (61.5%). From this initial survey, it would appear that there is 
currently a greater demand for molecular genetic and predictive genomic testing services 
than other types of analysis (Fig. 1B). Interestingly, pharmacogenomic testing is 
currently the least popular among patients, probably because this is a relatively new field 
and people are less educated with regard to the benefits of this type of test. Usually, 
patients are more interested in, and informed about, their own susceptibility to disease 
than they are about potential adverse drug reactions or inter-individual differences in 
drug metabolism and disposition, and the same may well be true for the attending 
physicians. Ironically, modulating or even avoiding a particular drug treatment is 
relatively straightforward but it is not necessarily so easy to avoid the consequences of 
an innate susceptibility to disease. Thus, in the longer term, it may well be that 
pharmacogenomic testing will deliver the most in terms of clinical benefit to the patient 
and hence will be more widely adopted in a clinical setting. 
The questionnaire responses indicated that physicians are the main target group 
for the genetic laboratories (92.3%), followed by the general public (43.2%) and other 
interested parties such as other genetic laboratories, diagnostic centres, hospitals, and 
pharmaceutical companies (30.8%). The main specialties that the diagnostic laboratories 
mainly address are obstetricians/gynecologists (92.3%), followed by pathologists 
(69.2%), cardiologists (69.2), psychiatrists (30.8%) and other specialties namely 
oncologists, pediatricians, hematologists, urologists, neurologists, and surgeons (Fig. 
2A). This may not be unexpected since obstetricians and gynecologists usually order 
molecular genetic and, particularly, cytogenetic tests to screen for fetal malformations, 
particularly in cases with a family history. In addition, psychiatrists, cardiologists and 
oncologists are the physicians who order pharmacogenomic tests more frequently, since 
these are the disciplines in which pharmacogenomic testing has been most widely 
adopted. Of course, other factors may influence the percentage of physicians ordering 
the genetic tests, e.g. the numbers of clinicians in different specialties, differential 
funding available to practitioners in each specialty, differences in genetics education 
between specialties, etc. Interestingly, in the context of paternity testing, lawyers can 
also be a target group of the genetic testing laboratory.  
In the case of the age range of the people undergoing genetic testing, the 
majority are aged between 35 and 60 years (92.3%), followed by people younger than 35 
years (76.9%). Perhaps unsurprisingly, people older than 60 years of age are less likely 
to undergo genetic testing (46.2%; Fig. 2B), most likely due to their lack of knowledge 
about the potential benefits of genetic analysis (Koromila and coworkers, in 
preparation). It might also be that people older than 60 are less likely to want genetic 
disease testing, as they are probably already quite knowledgeable about their existing 
pathologies from personal experience and less likely to want paternity testing for 
obvious reasons. However, one would perhaps expect this group to be more likely to 
avail themselves of genetic testing in an oncology context. As far as the source of the 
genetic material is concerned, peripheral blood was found to be the most commonly 
used DNA source (92.3%), followed by buccal swab samples (84.6%), tissue samples 
(e.g. paraffin-embedded tissue or fresh biopsies; 76.9%), saliva (53.9%) and other 
sources such as semen, urine, cell cultures (Fig. 3). The choice of sample is going to be 
very much test-dependent and hence very much a function of what tests the different 
companies perform. For example, buccal swabs and saliva samples may be more 
frequently used as a DNA source for predictive genomic testing, while peripheral blood 
will be used for molecular genetic testing services. Although the results obtained from 
the isolated DNA do not differ, physicians and the general public generally tend to 
prefer peripheral blood as the DNA source for genetic tests, since they appear to feel that 
this sampling and DNA isolation approach somehow has a more solid scientific basis as 
compared to the other DNA sources. 
An integral part of the questionnaire was the issue of the cost to the consumer of 
the available tests. The majority of these tests were cheaper than 300 EUR (Fig. 4) 
whereas the number of genetic tests performed decreased as the corresponding analysis 
costs increased (Fig. 4 and Supplementary information online). All pharmacogenomic 
tests offered were cheaper than 300 EUR, while in some cases the cost of the test was as 
low as 50 EUR when such tests are ordered and performed in bulk. 
Although the majority of private genetic testing laboratories performed genetic 
analysis with informed written consent from the patients (76.9%), several genetic 
laboratories did not fulfill this requirement, according to their responses to our survey. 
This finding underlines the need to make informed written consent a obligatory 
requirement for genetic testing in Greece and other European countries.  
It was however encouraging that all private genetic testing laboratories that 
responded to our survey had a genetic counselor working or collaborating with them. 
Although the majority of genetic testing laboratories have an ISO certificate (84.6%), 
and hence may be considered accredited, very few have been certified for the provision 
of genetic testing services specifically (ISO-15189 and/or ISO-17025; Burnett et al., 
2009), namely ISO-17025 (15.4%) and ISO-15189 (15.4%). The accreditation system in 
Greece follows that adopted in other European countries. The introduction of new 
genetic and pharmacogenomic tests occurs after consultation of the scientific literature 
for new research studies on genotype-phenotype correlations (76.9%), followed by 
recommendations from an internal scientific review group, to the company, Scientific 
Advisory Board or scientists (69.2%), external physicians (61.5%) or advisors (38.5%). 
As stated above, 61.8% of the private genetic laboratories offer 
pharmacogenomic testing services. These tests relate mostly to anticoagulant drugs 
(53.9%), followed by antidepressants and antipsychotic drugs (38.5%), cholesterol 
lowering drugs (30.8%), oncologic drugs (15.4%) and analgesics (30.8%; Fig. 5). 
Finally, we wished to understand the various marketing approaches adopted by each 
laboratory to attract test samples. According to our survey, the laboratory’s own website 
constituted the most frequently used means to inform both the general public and 
physicians about new genetic and pharmacogenomic tests being offered (both 92.3%; 
Fig. 6A, B). Physicians were also informed by attendance at scientific conferences 
(63.2%) and direct contact with sales representatives (63.2%), while only 23.1% 
obtained their information through educational seminars organized by the laboratories 
(Fig. 6A). Despite this, 46.2% of the genetic laboratories had participated as sponsors 
and 30.8% as exhibitors in a recent (2010) Greek medical or genetics-related conference, 
in which physicians mostly participate. By contrast, 61.5% of the genetic laboratories 
inform the general public of their available genetic and pharmacogenomic tests via 
custom produced advertising material (e.g. leaflets, brochures that are mailed to them 
directly, while only 23.1% employed advertisements in newspapers or magazines (Fig. 
6B). According to the survey (Fig. 6B), none of the responding genetic laboratories uses 
a call center to directly communicate their services to the general public by making 
unsolicited calls to tout for business. However, we are aware that at least one of the 
laboratories that failed to respond to our questionnaire uses this approach as part of its 
public outreach strategy. In addition, buccal swab sampling kits for genetic tests are sold 
over the counter in at least one chain of pharmacies in Greece, while other pharmacies 
provide the same sampling kit upon request.  
 
Discussion 
The rapid pace of development in the field of human genomic technologies has 
led to an exponential increase in the number of available genetic tests and a decrease in 
the relative cost of each genetic analysis. As a result, genetic testing services have 
become readily available to patients and the general public alike, whether to assess the 
risk of developing a life-threatening inherited disorder or to predict the efficacy of (or 
toxicity to) a specific drug. Indeed, it is estimated that more than 700.000 genetic tests 
are performed in Europe on an annual basis [Grimaldi et al., 2011], and this figure is 
expected to grow rapidly over the next few years. Although the number of public and 
private genetic testing laboratories continues to grow, little is known about the general 
landscape in which genetic testing services operate in many countries. Indeed, in many 
European countries, there are gaps in legislation covering genetic testing  
(https://www.eshg.org/fileadmin/www.eshg.org/documents/Europe/LegalWS/ReportES
HG-LegalWorkshop2010.pdf), and hence the different parties involved are not fully 
protected from unethical practices [Hogarth et al., 2008]. In Europe, there are significant 
differences between individual countries as far as genetic testing services are concerned. 
Although in many countries, there is an established regulatory framework and provisions 
for genetic testing, in other countries the area is still not properly regulated. The 
EuroGenTest Network (http://www.eurogentest.org) and EuroGenGuide 
(http://www.eurogenguide.org.uk) are some of the efforts that have been attempting not 
only to harmonize genetic testing services across Europe but also to provide guidance on 
genetic testing/analysis for patients and physicians. These commendable efforts 
notwithstanding, a detailed analysis of the current situation in European countries is 
currently lacking. For most of these countries, there are some reports, available through 
newsletters from the European Society of Human Genetics (http://www.eshg.org), but 
no comprehensive survey has ever been conducted. 
In a Greek context, the first genetics units appeared in Athens in the early 1960s 
and cytogenetic laboratories became the first to offer their services to the general public. 
Since 2003, at which time only 5 private genetic laboratories offered (a range of) genetic 
services in Greece, their number has increased significantly. However, the country still 
lacks formal genetics centers organized within a national genetic testing network, as in 
the United Kingdom (the UK Genetic Testing Network, which advises the NHS on 
genetic testing across the whole of the UK; http://www.ukgtn.nhs.uk/gtn/Home). Also, 
the number of physicians in full-time clinical genetics is extremely limited in the public 
sector, while at the same time there are a large number of well trained clinical scientists 
in genetics who cannot be absorbed despite the growing need for genetic services. 
University departments and public hospitals are usually under-staffed and under-paid 
owing to the lack of resources to support trained personnel. Recently, we initiated a 
major nationwide survey to try to understand the context of private genetic testing 
services in Greece and to explore how both the general public and physicians perceive 
genetics and genetic testing services. Such an analysis has not previously been 
performed and it was designed to address key aspects of genetic analysis such as ethics 
and education as well as insurance and confidentiality issues. In addition, our survey 
paid particular attention to pharmacogenomic testing since this emerging discipline is 
anticipated to have a central role in translational medicine. 
Our results from surveying the provision of genetic testing services from private 
laboratories showed that, at present, demand leans towards molecular genetic and 
cytogenetic testing, following many years of successful application of these approaches. 
According to the views of certain laboratories who offer this service, pharmaceutical 
companies in Greece attempt to discourage physicians from recommending 
pharmacogenomic testing, since this will tend to reduce the pharmaceutical companies’ 
profit margins. The argument that they use is that the pharmacogenomic test costs 
significantly more than simply trying out the drug in question. Moreover, given the 
recent emergence of this field, pharmacogenomic tests currently tend to be a low priority 
for customers of genetic testing companies (Fig. 1). This is however likely to change 
over time as a consequence of integrating pharmacogenomics into mainstream medical 
practice.  
Another interesting finding is the nature of the customer target group of private 
genetic testing laboratories, who are primarily physicians, in particular gynecologists 
(Fig. 2) and to a lesser extent pathologists, cardiologists, oncologists and psychiatrists. 
This result is not so unexpected given that the general public in Greece is strongly 
opposed to direct-access testing (Koromila and coworkers, in preparation). However, a 
significant fraction of laboratories (43.2%) receive test requests directly from patients. 
In this latter case, the presence of a qualified genetic counselor is required to accurately 
and reliably communicate the test result to the patient who requested the test. According 
to the laboratory personnel, physicians that refer patients to them for testing are not in a 
position to explain the test result, due to lack of the appropriate education and training. 
This finding concurs with the results obtained from the physicians’ survey (Koromila 
and coworkers, in preparation), where a significant proportion of physicians (particularly 
the older physicians) display a remarkable lack of knowledge of genetics. According to 
the laboratory personnel, the younger new generation physicians understand genetics 
much better and hence are not only in a better position to explain test results but also 
eager to encourage their patients to undergo genetic testing in the first place. We must be 
aware that it has only been relatively recently that molecular biology and genetics has 
been incorporated into mainstream university curricula as an integral part of medical, 
pharmacy and nursing studies at the undergraduate and graduate level.  
Another interesting finding from the genetic laboratories survey indicates that the 
means of communication with their target group is primarily via the company website 
(92.3%, both for physicians and patients), followed by advertising, scientific 
conferences and visits to physicians from sales representatives. The companies who 
responded to our survey indicated that they do not use call centers to make unsolicited 
calls to the general public to tout for business. However, the authors are aware of at least 
two private genetic laboratories in Athens who have either used this approach in the past 
or are currently using this approach in order to attract their clientele. We believe that this 
approach is wholly unethical since the general public is most unlikely to acquire a 
detailed understanding of the pros and cons of taking a particular genetic test by these 
means. Indeed, even if the ‘worried well’ are not actually misled by the company’s sales 
procedures, they will probably not be clear as to how they might benefit from the genetic 
test.  
One Greek pharmacy group has achieved a degree of notoriety by promoting 
genetic tests and selling DNA sampling kits to the public over the counter while other 
pharmacies are generally willing to order these sampling kits upon request. We have 
made enquiries with several pharmacies about the demand for these kits but it would 
appear that the demand is very low. Again, this finding concurs with the results from our 
general public survey (Koromila and coworkers, in preparation) indicating that only a 
small fraction of the general public would prefer a pharmacist to recommend a genetic 
test to. The Hellenic Society of Medical Geneticists (http://www.sige.gr; content in 
Greek) have recently published a warning about direct-access testing services being 
offered by Greek private genetic laboratories using call centers, stressing that these are 
highly specialized tests whose benefits and results cannot possibly be communicated by 
phone and by people who have not received the appropriate training. The Society has 
also stressed that if there were proper regulatory and legal frameworks in place, they 
would prevent such practices in what is still fortunately a fairly small number of genetic 
laboratories. It is noteworthy that the first law on the regulation of the practice of 
medical genetics was passed by the Greek Parliament back in 1980, but it has never been 
implemented. Cost-wise, the provision of genetic testing services is reasonably cheap 
with the majority of genetic tests costing less than 300 EUR, and in certain cases below 
50 EUR. Bearing in mind the continuously falling costs of genetic analyses, the current 
profit margins of these laboratories are likely to be still high and hence there is 
considerable room for price reductions in the future (at least in a truly competitive 
market).  
From our current study, it seems quite evident that the provision of genetic 
services in Greece has not yet benefited from any central planning, nor has it yet 
acquired an appropriate regulatory framework. This of course may resemble the 
situation pertaining in other European countries, although for some of them (like the 
UK, Germany, the Netherlands and several others), genetic testing is well organized. 
There are no professional guidelines concerning quality assessment of genetic services 
in Greece, although recently, more optimistically, many molecular genetic laboratories 
have joined quality assessment schemes for genetic disorders organized by the European 
Molecular Genetics Quality Network [EMQN; http://www.emqn.org/emqn/Home; 
Dequeker et al., 2001]. Despite this, very few Greek genetic laboratories have been 
accredited with an ISO-15189 or ISO-17025 while other genetic laboratories are 
accredited with an ISO-9001 or equivalent, and hence are not properly certified for 
genetic testing. 
In essence, our study provides the basis for a critical appraisal of the private 
genetic testing environment in Greece and provides a model for replication in other 
European countries to assess the landscape of genetic testing services.   
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Figure legends 
 
Figure 1 
The various types of genetic testing analysis offered by private genetic laboratories in 
Greece (A) and their relative proportions in terms of the demand for these tests (B).  
 
Figure 2 
Overview of the main target group of private genetic laboratories in Greece. A. 
Summary of the key medical specialties that refer patients to private genetic laboratories 
for genetic testing. B. Relative proportions of the age range of patients undergoing 
private genetic testing in Greece. 
 
Figure 3 
Relative proportions of the main DNA sources used for genetic analysis; *: Refer to text 
for details.  
 
Figure 4 
Marketing channels employed by the private genetic laboratories to contact their main 
target groups, namely physicians (A) and the general public (B); *: Refer to text for 
details.  
 
Figure 5 
Breakdown of the costs of genetic analysis by type evaluated in this survey. 
 
Figure 6 
Relative proportions of the main types of drugs for which pharmacogenomic tests are 
offered by private genetic laboratories; *: Refer to text for details.  
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Figure 6 
Table 1 
Locations of the private genetic laboratories invited to participate in the study. 
 
 Number of laboratories 
City Invited Responded % 
Athens 12 10 83.3 
Piraeus 2 0 0 
Thessaloniki 1 1 100 
Patras 1 1 100 
Alexandroupolis 1 0 0 
Heraklion 1 1 100 
TOTAL 18 13 72.2 
 
